FDA Chief Takes on Health Care Monopolies

Ron Sachs/CNP via ZUMA

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Scott Gottlieb, commissioner of the FDA, spoke today to a meeting of the insurance industry’s main lobbying group. He basically accused them of conspiring to keep prices high on expensive biosimilar drugs:

Too often, we see situations where consolidated firms — the PBMs,¹ the distributors, and the drug stores — team up with payors [i.e., insurance companies]. They use their individual market power to effectively split some of the monopoly rents with large manufacturers and other intermediaries rather than passing on the saving garnered from competition to patients and employers….And so, we continue to see a backlash against these Kabuki drug-pricing constructs — constructs that obscure profit taking across the supply chain that drives up costs; that expose consumers to high out of pocket spending; and that actively discourage competition.

Patients shouldn’t be penalized by their biology if they need a drug that isn’t on formulary….After all, what’s the point of a big co-pay on a costly cancer drug? Is a patient really in a position to make an economically-based decision? Is the co-pay going to discourage overutilization? Is someone in this situation voluntary seeking chemo? Of course not. Yet the big co-pay or rebate on the costly drug can help offset insurers’ payments to the pharmacy, and reduce average insurance premiums. But sick people aren’t supposed to be subsidizing the healthy. That’s exactly the opposite of what most people thought they were buying when the bought into the notion of having insurance.

….Patient access to these innovations will depend on reforms that require every incumbent in the drug supply chain to take greater restraint for putting patients at the heart of their decision-making process….We’re not there today. Instead, we have a lot of finger pointing that ignores shared complicity for pricing practices that are eroding trust in both payors and innovators. I hope that you’ll act before that trust is eroded completely.

Good for Gottlieb. Pharmacy benefit managers were originally a good idea intended to truly manage the complicated business of negotiating drug prices. As usual, though, things got out of hand when everyone realized they could be used to enrich themselves instead. These days they accomplish little except to make the entire procurement process so opaque that no one can reasonably figure out what the real cost of a drug is. That’s good for just about everyone except patients.

And since consolidation is one of my bugbears, it’s worth noting Gottlieb’s raw data: “The top three PBMs control more than two-thirds of the market; the top three wholesalers more than 80%; and the top five pharmacies more than 50%.” In the past, the mere fact of market power this strong would have been enough to spur antitrust action. But after the Bork revolution, size didn’t matter. What mattered was whether big companies could argue that bigness was good for consumers. Needless to say, big companies are very, very good at making this argument, and so antitrust actions have dwindled to a trickle. It’s long past time for a counter-revolution that returns us to the era in which consolidation beyond a certain size is ipso facto a reason for antitrust action.

¹PBM = pharmacy benefit managers. Insurance companies hire PBMs to negotiate formularies and drug prices. As Gottlieb notes, two-thirds of the PBM market is controlled by three giant players: ExpressScripts, CVS Caremark, and OptumRx. PBMs are widely believed to abuse their position by negotiating obscure rebates and endless fees that end up increasing costs for patients.

FOLLOW THE MONEY

Corporations and billionaires don’t fund journalism like ours that exists to shake things up. Instead, support from readers allows Mother Jones to call it like it is without fear, favor, or false equivalence.

And right now, a longtime friend of Mother Jones has pledged an incredibly generous gift to inspire—and double—giving from online readers. That's huge! Because you can see that our fall fundraising drive is well behind the $325,000 we need to raise. So if you agree that in-depth, fiercely independent journalism matters right now, please support our work and help us raise the money it takes to keep Mother Jones charging hard. Your gift, and all online donations up to $94,000 total, will be matched and go twice as far—but only until the November 9 deadline.

$400,000 to go: Please help us pick up the pace!

payment methods

FOLLOW THE MONEY

Corporations and billionaires don’t fund journalism like ours that exists to shake things up. Instead, support from readers allows Mother Jones to call it like it is without fear, favor, or false equivalence.

And right now, a longtime friend of Mother Jones has pledged an incredibly generous gift to inspire—and double—giving from online readers. That's huge! Because you can see that our fall fundraising drive is well behind the $325,000 we need to raise. So if you agree that in-depth, fiercely independent journalism matters right now, please support our work and help us raise the money it takes to keep Mother Jones charging hard. Your gift, and all online donations up $94,000 total, will be matched and go twice as far—but only until the November 9 deadline.

$400,000 to go: Please help us pick up the pace!

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate